Synthesis of locked cyclohexene and cyclohexane nucleic acids (LCeNA and LCNA) with modified adenosine units

Abstract

We describe here the preparation of conformationally locked cyclohexane nucleic acids designed as hybrids between locked nucleic acids (LNAs) and cyclohexene nucleic acids (CeNAs), both of which excel in hybridization with complementary RNAs. We have accomplished the synthesis of these adenine derivatives starting from a simple ketoester and installed all four chiral centres by means of total synthesis. The acquired monomers were incorporated into nonamer oligonucleotides.

---

Introduction

Oligonucleotides with modified sugar moieties have found many applications in modern technologies such as antisense oligonucleotides, RNA interference (RNAi), ribozymes, DNAzymes and aptamers. The stabilization of the duplexes with complementary mRNA of interest is an essential concept for oligonucleotide-mediated regulation of the gene expression. Extensive hybridization with the target sequence and selectivity towards mRNA in comparison with affinity to complementary DNA are important features of the desired technologies.¹

Although various sugar modifications have led to the enhancement of the hybridization properties of antisense oligonucleotides, probably the most famous modifications are based on monomers with a bridge between the 2′ and 4′ positions of the ribose ring. This results in the stabilization of the 3′-endo conformation and the formation of bridged nucleic acids (BNAs).² Imanishi's³ and Wengel's⁴ groups have independently synthesized monomers for 2′,4′-bridged nucleic acids/locked nucleic acids (LNA, 1) and reported their hybridization properties after incorporation into oligonucleotides (Fig. 1). LNAs have also been successfully used for both RNAi⁵ and selection of aptamers.⁶ Since then, a number of compounds with alternative bridges (e.g.2–4) have been prepared, especially in order to increase the nuclease resistance of the resulting oligonucleosides.⁷ Carba-LNAs (e.g.2)⁸ have also been prepared. They seem to possess a significantly increased nuclease resistance in comparison with traditional LNAs without a dramatic effect on the RNAse H mediated cleavage of the target RNA.⁹ Recently LNAs modified on the nucleobase have been reported as well.¹⁰

Fig. 1 The structures of selected nucleic acids with sugar modification including LNA analogues (1–4) and six-membered carbohydrate mimics (5–7).

In contrast to LNA-based oligonucleotides, which usually form stable duplexes with both RNA and DNA, cyclohexene nucleic acids (CeNA, 5), developed by Herdewijn et al., exert significant selectivity in hybridization with RNA over DNA.¹¹ The same research team has also suggested that the cyclohexene moiety can serve as an appropriate bioisostere of the natural furanose ring^11b and proved that this pseudosugar exerts significant flexibility while being incorporated into the structure of oligonucleotides. The crystal structures of duplexes with complementary DNA and RNA oligomers have clearly demonstrated that the cyclohexene moiety can interconvert between two distinct conformations ²H₃ (similar to C2′-endo) and ³H₂ (similar to C3′-endo).^12,13

Recently, Seth et al. have shown that 2′-fluoro hexitol nucleic acids (FHNA, 6) exhibit higher duplex stability compared to 2′-fluoro CeNA (F-CeNA, 7) due to higher rigidity and superior stabilization in C3′-endo-like conformation.^14,25

The major objective of our presented study was the preparation of hybrid derivatives merging LNAs and CeNAs in order to stabilize the cyclohexene moiety in ³H₂ conformation resembling the C3′-endo, which is preferred by CeNA while forming a duplex with complementary RNA strands.¹³ In addition, the synthesis of locked cyclohexene nucleic acid (LCeNA) monomers made it easy to obtain saturated monomers bearing a cyclohexane ring instead of the original cyclohexene one (LCNA).

Although the obvious way to reach these compounds in an asymmetric fashion led through extending the synthesis of CeNA by methods for the preparation of LNA from sugar precursors,¹⁵ we decided to explore a synthetic approach, which would result in this type of compound starting from simple precursors avoiding the use of a chiral pool or enzymatic resolution of synthetically complicated nucleosides. In order to be able to determine the enantiomeric purity of our compounds, we initially performed racemic synthesis of the desired monomers (see the ESI†).

Results and discussion

The retrosynthetic analysis is outlined in Fig. 2. The crucial step of the synthesis is the construction of the first stereogenic centre by Michael conjugated addition of the acrolein to starting material 8 catalysed by the quinine based organocatalyst (Q-PHN-OH) immediately followed by cyclization to build a bicyclic ring system (bicyclo[3.2.1]octane). Further transformations of the functional groups lead to the desired final nucleoside 25.

Fig. 2 Retrosynthetic analysis.

The asymmetric synthesis of the desired monomers started from the ester 8¹⁶ (Scheme 1), which was treated with acrolein together with a quinine organocatalyst (Q-PHN-OH) by following the published synthetic protocol.¹⁷ The crude aldehyde intermediate 8a was cyclized with cesium carbonate¹⁸ in toluene to afford a mixture of bicyclic compounds 9a and 9b (87% yield, 2 steps, ratio ∼3 : 2, GC-MS analysis). Alcohols 9a and 9b were used as a mixture (Scheme 1), their keto group protected as a ketal and the ester group of 10 was reduced by lithium aluminum hydride to an inseparable diastereomeric mixture of alcohols 11. The primary hydroxy group was protected by benzoylation at low temperature and the obtained mixture of the monobenzoylated compounds 13 (13a, 13b, separable) and the dibenzoylated compound 12 (only the compound with an equatorial hydroxyl group was dibenzoylated) was separated. The benzoylation procedure employing BzCN was also attempted but without any improvement in the yields of the monobenzoylated products 13. Compound 12 can be easily methanolyzed in high yield to the starting diol 11, which can be re-used in the benzoylation reaction. In one step, the hydroxy group of 13 was oxidized to a keto group and a double bond was introduced to the scaffold by IBX oxidation according to the procedure described by Nicolaou.¹⁹ This procedure progressed smoothly with an excellent yield (83%). Allylketone 14 was then subjected to the Luche reduction²⁰ and the obtained alcohols 15 and 16 were easily separated by column chromatography. The undesired alcohol 15 can be oxidized back to ketone 14 by manganese dioxide and thus recycled.

Scheme 1 Synthesis of compound 16. Reagents and conditions: (i) (a) Q-PHN-OH,¹⁷ acrolein, CH₂Cl₂, −25 °C; (b) Cs₂CO₃, toluene, r.t.. (ii) ethylene glycol, PPTS, benzene, 100 °C; (iii) LiAlH₄, Et₂O; (iv) BzCl, pyridine, CH₂Cl₂, −40 °C; (v) MeONa, MeOH; (vi) IBX, DMSO, TsOH, 90 °C; (vii), NaBH₄, CeCl₃, MeOH, 0 °C; (viii) MnO₂, CH₂Cl₂.

The ketone-protecting group of 16 was easily removed by the reaction with p-toluenesulfonic acid in a refluxing acetone–water mixture (Scheme 2). The keto group of the derivative 17 was then reduced to a hydroxy group by sodium triacetoxyborohydride. The hydroxy group in the position C-4 participates in this reaction and allows to prepare exclusively the product with the desired orientation of the C-8 hydroxy group in diol 18.²¹ Although we tried numerous methodologies for the direct introduction of the purine nucleobase (including Tsuji–Trost reaction, Mitsunobu reaction and various direct alkylation methods) using diversely protected derivatives of compound 18 and its congeners with opposite configuration of the allylic hydroxyl, they all failed to give an appropriate product either due to low reactivity or undesired allylic rearrangements resulting in complex mixtures of products. Both the hydroxy groups were sequentially protected afterwards, the allylic hydroxyl was selectively protected by the TBDMS group and the C-8 hydroxyl by benzoylation. The TBDMS group was then cleaved by TBAF/acetic acid (the reaction mixture is less basic) at an elevated temperature (the reaction at r.t. is relatively slow) and the free allylic hydroxy group was converted to chloro derivative 21, followed by the introduction of the azido group by NaN₃. At this stage, we were able to separate isomers 22 and 22a (a product of the allylic rearrangement) and we also discovered that the undesired isomer 22a can be easily converted to 22 by standing in acetonitrile solution or better by heating this solution overnight.²² The allylic rearrangement of 22a was monitored by ¹H NMR spectroscopy (see the ESI†).

Scheme 2 Synthesis of nucleosides 25 and 26. Reagents and conditions: (i) TsOH, acetone–H₂O, reflux; (ii) NaBH(OAc)₃, AcOH, CH₃CN, 0 °C to r.t.; (iii) (a) TBDMSCl, imidazole, CH₂Cl₂, 0 °C, (b) BzCl, pyridine, r.t.; (iv) TBAF, AcOH–THF, 60 °C; (v) NCS, PPh₃, CH₂Cl₂, 0 °C; (vi) NaN₃, DMF, 65 °C; (vii) CH₃CN, reflux; (ix) (a) PPh₃, THF, r.t., (b) H₂O, (c) KOH, EtOH–H₂O, reflux; (x) 4,6-dichloro-5-formamidopyrimidine, DIPEA, n-BuOH, MW, 160 °C; (xi) NH₃–EtOH, MW, 140 °C; (xii) H₂ (10 bar), Pd(OH)₂/C, MeOH, 50 °C.

The key amine 23 was prepared by the Staudinger reaction, followed by the removal of the benzoyl protecting groups under basic conditions (Scheme 2). A purine nucleobase was then introduced in moderate yield (42%) by a recently described MW-assisted build-up protocol.²³ Chloropurine derivative 24 was converted to adenine nucleoside 25 by ammonolysis with ethanolic ammonia under microwave conditions.^23,24 The enantiomeric purity of this LCeNA monomer 25 was determined by chiral HPLC, which assessed the enantiomeric purity above 98%. The saturated analogue 26 was obtained after hydrogenation in high yield (89%). Both nucleosides (25 and 26) were used as building blocks for the synthesis of monomeric phosphoramidite units, which were subsequently used for the solid-state oligonucleotide synthesis.

All the compounds were appropriately characterized by ¹H and ¹³C NMR and also by 2D NMR techniques (COSY, HSQC, HMBC). The configuration of the chiral centres at C8 and C4 of compound 25 was confirmed by 2D NMR techniques (COSY, ROESY). In the COSY spectrum, 2- and 3-bond spin–spin interactions are visible as cross-peaks. When the hydrogen atoms are in a W-like arrangement, it is possible to see 4-bond long-range couplings. Due to this fact, it was possible to confirm stereochemistry at C-8, where we found W-like long-range couplings between H8 and H7 (Fig. 3 top). The configuration was also confirmed by the ROESY spectrum, where the cross-peaks correspond to the through-space interactions. The H8–H8′ cross-peak clearly determined not only the configuration at the C8 atom, but also the C4 atom; the nucleobase must be above the cycle. For nucleoside 25 we also calculated spin–spin coupling constants by the DFT method (B3LYP/6-31+G(d,p)), which were in agreement with the experimental data (see Table S3 in ESI†).

Fig. 3 Region of COSY (in blue) and ROESY spectrum (in red) for compound 25. W-like shaped long-range coupling constant between H8 and H7-endo clearly determined the configuration at carbon C-8. Through-space interaction H8–H8′ confirmed the configuration at carbon C-4.

Synthesis of the phosphoramidites 29 and 31 which were used in the solid phase oligonucleotide synthesis is depicted in Scheme 3. We used a traditional approach and obtained the desired compounds in good yields. The obtained phosphoramidites 29 and 31 were then used in the classical trityl-off phosphoramidite method for solid-supported oligonucleotide synthesis.

Scheme 3 Synthesis of phosphoramidites 29 and 31. Reagents and conditions: (i) (a) TMSCl, pyridine, 0 °C, (b) BzCl, pyridine, r.t., (c) aq. NH₃, MeOH; (ii) DMTrCl, pyridine, r.t.; (iii) 2-cyanoethyl N,N-diisopropylchlorophosphoramidite, DIPEA, THF, r.t.; (iv) (a) dimethylacetal-N,N-dibutylformamide, MeOH, r.t., (b) DMTrCl, pyridine, r.t.; CNE = cyanoethyl.

The hybridization properties of the modified oligonucleotides with their natural DNA and RNA counterparts were evaluated by UV thermal denaturation experiments and the obtained T_m values were compared with those of the corresponding unmodified duplexes (Table 1).

Table 1 Thermal stability of modified oligonucleotide duplexes^a

Oligonucleotide	ssRNA Tm (ΔTm)^b	ssDNA Tm (ΔTm)^b
a 4 μM duplex in 50 mM NaH2PO4–Na2HPO4 pH 7.2 with 100 mM NaCl. b per modification.
5′-d(GCA̲^25TA̲^25TCA̲^25C)	22.0 (−4.3 °C)	No comp. form.
5′-r(GCA̲^25UA̲^25UCA̲^25C)	23.0 (−7.7 °C)	22.0 (-4.3 °C)
5′-d(GCA̲^26TA̲^26TCA̲^26C)	No comp. form.	No comp. form.
5′-r(GCA̲^26UA̲^26UCA̲^26C)	No comp. form.	No comp. form.

---

To our surprise, a striking destabilization effect was observed for both LCeNA and LCNA. Although some destabilization was observed by Migawa et al.²⁵ on structural related cANA derivatives, the drop in affinity is significantly larger in this case and cannot be clarified by the explanation suggested in their work, because the repulsion of the hydrogen in the bridge and the six-membered pseudosugar ring in cANA and LCeNA should lead to opposite effects (Fig. 4). Unfortunately, similar destabilization effects were observed also for homooligomers prepared from both LCeNA and LCNA subunits while hybridized with complementary oligothymidylates (see the ESI†).

Fig. 4 In contrast to the preferred conformation of cANA, LCeNA should adopt a conformation that situates the nucleobase in an “axial-like” orientation due to the repulsion of the hydrogen atom of the –CH₂CH₂– bridge and the hydrogen atom vicinal to the nucleobase.

To shed some light on the significant destabilization of the rLCeNA-RNA duplex, we performed the molecular dynamics simulations of RNA duplexes that included normal and locked units. (For a detailed analysis of the calculated results, structural models, and calculation method see ESI†). The values of backbone torsion angles α, γ, and δ calculated for the units of RNA oligonucleotides (Fig. S8–S13†) were analysed and statistical distributions of the torsion angles (Fig. S14†) were compared. The calculations unveiled a significant structural disorder of modified duplexes as compared to the A-RNA structure that was calculated for the duplex that included normal units. The deviations of modified oligonucleotides from canonical A-RNA occurred particularly owing to the irregular behaviour of the normal units neighbouring with modified units. The modified units were structurally more rigid though their behaviour was abnormal. In particular, the sugar of modified nucleosides was locked (δ torsion was ca. 60°) while the sugar of the normal units was flexible (δ torsion ranged from ca. 80° to ca. 160°). The overall values of α backbone torsions in the neighbourhood of modified residues were smaller by ca. 30° as compared to the typical value known for canonical A-RNA. The α-distribution calculated for locked units broadened, which indicated larger amplitudes of motion near phosphate. The α and γ torsions of phosphate groups bridging the locked unit with neighbouring normal units frequently flipped between the values characteristic to A-RNA, α/γ ≈ 290°/70°, and the values calculated owing to locked units, α/γ ≈ 180°/180°. The α-distributions of a normal A-RNA duplex were always single-modal and centered at 290° in contrast to bi- or even tri-modal α-distributions calculated in the neighbourhood of locked units (Fig. S14†). The calculations indicated instabilities and structural disorders of the normal residues in the neighbourhood of modified units. Moreover, the occurrence of α/γ flips depended on the positioning of phosphate groups with respect to 3′-end and 5′-end of locked units. The conformationally locked residues of RNA duplexes thus induced particularly irregular behaviour of backbone phosphates in the vicinity of the modified units.

Conclusions

In conclusion, we have prepared novel modified oligonucleotides containing monomers based on bicyclo[3.2.1]octene and octane skeletons as hybrids of CeNA/CNA and LNA. The appropriate monomers were synthesized from a simple achiral precursor – ketoester 8. As far as we know, this is the first synthesis of the LNA analogues performed by a total synthetic approach. Our molecular dynamics calculations suggest that a surprisingly low affinity of the modified oligonucleotides towards the complementary DNA and RNA results from the irregular behaviour of the nucleotides neighbouring with the locked units. The overall structure of the duplex containing locked units was significantly disordered and more conformationally labile in comparison with an A-RNA form of a normal duplex.

Experimental section

General

Melting points were determined on a Büchi B-540 apparatus. NMR spectra (δ, ppm; J, Hz) were measured on a Bruker Avance II-600 and/or Bruker Avance II-500 instruments (600.1 or 500.0 MHz for ¹H and 150.9 or 125.7 MHz for ¹³C) in hexadeuterated dimethyl sulfoxide and referenced to the solvent signal (δ 2.50 and 39.70, respectively). Mass spectra were measured on a LTQ Orbitrap XL (Thermo Fisher Scientific) by electrospray ionization (ESI). Column chromatography was performed on Silica gel 60 (Fluka) and thin-layer chromatography (TLC) on Silica gel 60 F254 foils (Merck). Solvents were evaporated at 2 kPa and bath temperature 30–60 °C; the compounds were dried at 13 Pa and 50 °C. The elemental analyses were obtained using a Perkin–Elmer CHN Analyzer 2400, Series II Sys (Perkin–Elmer). The elemental compositions for all compounds agreed to within ±0.4% of the calculated values. For all the tested compounds satisfactory elemental analysis was obtained supporting >95% purity. Optical rotation was measured on a polarimeter Autopol IV (Rudolph Research Analytical) at 589 nm wavelength in chloroform or methanol. Microwave syntheses were carried out using a CEM Discover instrument with a single-mode cavity and focused microwave heating (microwave power supply 0–300 W, 1 W increments, sealed vessel mode, pressure range 0–20 bar). GC-MS analyses were recorded by using a 5975B quadrupole mass spectrometer coupled to a 6890N gas chromatograph (Agilent, Santa Clara, CA, USA) equipped with a Phenomenex ZB-5 HT capillary column (30 m × 0.25 mm, film thickness 0.25 μm); temperature: 60 °C (2 min), then 10 °C min⁻¹ to 320 °C (10 min).

Preparation of compounds 9a and 9b

To a mixture of starting material 8 (9.05 g, 49.1 mmol) and a catalyst Q-PHN-OH¹⁷ (2.40 g, 4.93 mmol, 0.1 eq.) in dry CH₂Cl₂ (100 mL) at −25 °C under an argon atmosphere, a solution of acrolein (8.23 mL, 123 mmol, 2.5 eq.) in CH₂Cl₂ (30 mL) was added dropwise. The reaction mixture was occasionally stirred (>95% of time without stirring) and kept at −25 °C for 24 h. Then the reaction mixture was poured into a silica gel column (200 g, Et₂O) and the crude product was eluted with Et₂O. Fractions containing the product were collected and evaporated to afford a crude intermediate (12.53 g) which was used immediately in the next step. The crude catalyst was then eluted from the column using methanol and recycled (chromatography on a silica gel column in CH₂Cl₂–ethanol 25 : 1). The crude intermediate was dissolved in toluene (350 mL), cesium carbonate (8.48 g, 26 mmol) was then added and the reaction mixture was stirred at r.t. overnight. Solids were removed by filtration through Celite and the filtrate was evaporated. The product was purified on a silica gel column (250 g, toluene–ethyl acetate 3 : 1 → 2 : 1) to afford 9.416 g (80%) of the mixture 9a and 9b (GC chromatogram, Fig. S1†). Analytical samples of both isomers were obtained by column chromatography of the sample (300 mg of the mixture, 100 g of silica gel, toluene–ethyl acetate 3 : 1 → 2 : 1). For the determination of the optical purity of this step see the ESI.†

tert-Butyl (1S,4S,5S)-4-hydroxy-8-oxobicyclo[3.2.1]octane-1-carboxylate (9a). Viscous oil. [α]²⁰_D = −22.8 (c 0.325, CHCl₃). Found: C, 65.26; H, 8.39. Calc. for C₁₃H₂₀O₄: C, 64.98; H, 8.39%. ¹H NMR (500 MHz, d6-DMSO): δ 1.39 (s, 9H, tBu), 1.48–1.58 (m, 1H, H-3a), 1.67–1.87 (m, 5H, H-3b, H-7a, H-6ex, H-2), 1.90–1.97 (m, 1 H, H-6en), 2.30–2.36 (m, 1H, H-7b), 2.38 (dd, J_5–4 = 3.1, J_5–6ex = 6.7, 1H, H-5), 3.76–3.82 (m, 1H, H-4), 5.14 (d, J_OH-4 = 4.5, 1H, OH). ¹³C NMR (125.7 MHz, d6-DMSO): δ 16.02 (C-6), 26.52 and 26.63 (C-3 and C-7), 27.86 (C(CH₃)₃), 31.05 (C-2), 54.37 (C-5), 57.05 (C-1), 73.00 (C-4), 80.47 (C(CH₃)₃), 170.27 (COOtBu), 211.58 (C-8). ESI MS, m/z (rel%): 263 (100) [M + Na]. HRMS: calcd for [M + Na]: 263.12538, found: 263.12541.

tert-Butyl (1S,4R,5S)-4-hydroxy-8-oxobicyclo[3.2.1]octane-1-carboxylate (9b). Viscous oil. [α]²⁰_D = −5.5 (c 0.381, CHCl₃). Found: C, 65.17; H, 8.56. Calc. for C₁₃H₂₀O₄: C, 64.98; H, 8.39%. ¹H NMR (500 MHz, d6-DMSO): δ 1.39 (s, 9H, tBu), 1.49 (ddm, J_3ax–2ax = 5.3, J_gem = 14.8, 1H, H-3ax), 1.57 (dddd, J_6en–5 = 0.8, J_6en–7ex = 4.4, J_6en–7en = 10.8, J_gem = 13.3, 1H, H-6en), 1.77–1.85 (m, 2H, H-2eq, H-6ex), 1.87–1.95 (m, 2H, H-7en, H-3eq), 2.25–2.36 (m, 3H, H-5, H-2ax, H-7ex), 4.06–4.09 (m, 1H, H-4), 4.99 (dm, J_OH-4 = 2.8, 1H, OH). ¹³C NMR (125.7 MHz, d6-DMSO): δ 18.67 (C-6), 25.16 (C-7), 25.51(C-7), 27.94 (C(CH₃)₃), 33.35 (C-2), 51.96 (C-5), 57.28 (C-1), 76.38 (C-4), 80.34 (C(CH₃)₃), 170.42 (COOtBu), 211.44 (C-8). ESI MS, m/z (rel%): 263 (100) [M + Na]. HRMS: calcd for [M + Na]: 263.12538, found: 263.12541.

Preparation of compounds 10a and 10b

A mixture of alcohols 9a and 9b (9.1 g, 37.9 mmol) was dissolved in benzene (320 mL) and pyridinium p-toluenesulfonate (1.97 g, 7.8 mmol) and ethylene glycol (9.2 mL) were then added. The reaction mixture was heated to reflux with a Dean–Stark trap for 24 hours and then cooled to r.t., diluted with ethyl acetate (450 mL) and washed with water (300 mL) and saturated aq. sodium bicarbonate (2 × 300 mL). The organic phase was dried over sodium sulfate and evaporated. The residue was purified on a silica gel column (350 g, toluene–ethyl acetate 1 : 1) to obtain 9.15 g (85%) of the mixture of 10a and 10b. Analytical samples of both isomers were obtained after chromatography of the sample (300 mg of the mixture, toluene–ethyl acetate 3 : 1 → 2 : 1).

tert-Butyl (1S,4S,5S)-4-hydroxy-1H-spiro[bicyclo[3.2.1]octane-8,2′-[1,3]dioxolane]-1-carboxylate (10a). Viscous oil. [α]²⁰_D = −22.4 (c 0.277, CHCl₃). Found: C, 63.24; H, 8.53. Calc. for C₁₅H₂₄O₅: C, 63.36; H, 8.51%. ¹H NMR (500 MHz, d6-DMSO): δ 1.14–1.22 (m, 1H, H-3eq), 1.32–1.49 (m, 12H, tBu, H-2eq, H-6ex, H-7en), 1.54–1.60 (m, 1H, H-6en), 1.61–1.67 (m, 1H, H-3ax), 1.82 (dd, J_5–4 = 3.1, J_5–6ex = 6.4, 1H, H-5), 1.95–2.02 (m, 1H, H-2ax), 2.17–2.24 (m, 1H, H-7ex), 3.76–3.91 (m, 5H, −OCH₂CH₂O−, H-4), 4.45 (d, J_OH-4 = 4.6, 1H, OH). ¹³C NMR (150.92 MHz, d6-DMSO): δ 17.70 (C-6), 26.37 (C-3), 27.80 (C(CH₃)₃), 28.10 (C-7), 29.85 (C-2), 49.23 (C-5), 52.38 (C-1), 63.93 and 65.42 (−OCH₂CH₂O−), 67.78 (C-4), 79.26 (C(CH₃)₃), 116.08 (C-8), 172.49 (COOtBu). ESI MS, m/z (rel%): 307 (100) [M + Na]. HRMS: calcd for [M + Na]: 307.15160, found: 307.15163.

tert-Butyl (1S,4R,5S)-4-hydroxy-1H-spiro[bicyclo[3.2.1]octane-8,2′-[1,3]dioxolane]-1-carboxylate (10b). Viscous oil. [α]²⁰_D = −21.7 (c 0.373, CHCl₃). Found: C, 63.29; H, 8.69. Calc. for C₁₅H₂₄O₅: C, 63.36; H, 8.51%. ¹H NMR (500 MHz, d6-DMSO): δ 1.14 (ddd, J_6en–7ex = 4.4, J_6en–7en = 10.0, J_gem = 13.0, 1H, H-6en), 1.38 (s, 9H, tBu), 1.39–1.46 (m, 2H, H-2eq, H-3eq), 1.56 (ddd, J_7en–6ex = 4.7, J_7en–6en = 10.8, J_gem = 13.3, 1H, H-7en), 1.64–1.73 (m, 2H, H-3ax, H-6ex), 1.91 (dd, J_5–4 = 4.0, J_5–6ex = 7.2, 1H, H-5), 2.18 (dddm, J_7ex–6en = 4.4, J_7ex–6ex = 12.5, J_gem = 13.3, 1H, H-7ex), 2.32 (tdd, J_2ax–7ex = 1.4, J_2ax–3ax = 5.6, J_2ax–3eq = J_gem = 13.7, 1H, H-2ax), 3.67–3.72 (m, 1H, H-4), 3.82–4.03 (m, 4H, −OCH₂CH₂O−), 4.14 (d, J_OH-4 = 9.6, 1H, OH). ¹³C NMR (125.7 MHz, d6-DMSO): δ 21.60 (C-6), 25.99 (C-3), 26.38 (C-7), 27.82 (C(CH₃)₃), 29.36 (C-2), 45.37 (C-5), 52.48 (C-1), 63.98 and 65.73 (−OCH₂CH₂O−), 72.65 (C-4), 79.48 (C(CH₃)₃), 116.32 (C-8), 172.00 (COOtBu). ESI MS, m/z (rel%): 307 (100) [M + Na]. HRMS: calcd for [M + Na]: 307.15160, found: 307.15165.

Preparation of compounds 13a and 13b

A mixture of alcohols 10a and 10b (9.79 g, 34.43 mmol) was dissolved in anhydrous ether (1000 mL) and cooled down with ice bath (argon atmosphere). A solution of LiAlH₄ in THF (60.5 mL, 1 M solution, 1.75 eq.) was added dropwise in 30 minutes. The reaction was allowed to slowly reach room temperature and was stirred overnight, then cooled again to 0 °C and quenched with ice. Solids were removed by filtration through a Celite pad and thoroughly washed with ethanol. The filtrate was concentrated and the residue was chromatographed on a silica gel column (300 g, ethyl acetate–ethanol 20 : 1) to afford an inseparable mixture of the diols (11, 6.86 g, 92%).

(1S,5R)-1-(Hydroxymethyl)spiro[bicyclo[3.2.1]octane-8,2′-[1,3]dioxolan]-4-ol (11). Viscous oil. Found: C, 61.78; H, 8.43. Calc. for C₁₁H₁₈O₄: C, 61.66; H, 8.47%. CI MS, m/z (rel%): 214 (5) [M + H], 197 (100) [M − OH]. HRMS: calcd for [M + H]: 215.1283, found: 215.1286.

Benzoylation of the diol 11

Compound 11 (7.267 g, 33.9 mmol) was dissolved in CH₂Cl₂ (300 mL) and pyridine was added (5.5 mL, 68 mmol). The reaction mixture was cooled to −40 °C and a solution of benzoyl chloride (5.9 mL, 50.8 mmol) in CH₂Cl₂ (30 mL) was added dropwise for 1 h and the reaction mixture was stirred at −40 °C for 13 hours. The reaction was quenched with methanol and all volatiles were evaporated. The residue was dissolved in ethyl acetate (700 mL) and washed with water (300 mL) and satd sodium bicarbonate (300 mL), dried with sodium sulfate and evaporated. The residue was chromatographed on silica gel (400 g, toluene–ethyl acetate 4 : 1 → 1 : 1) to afford 3.580 g of 12 (25%) and 7.261 g of 13a + 13b (67%, mixture). The mixture of monobenzoylated compounds 13a + 13b was separated on a small scale by column chromatography (250 mg of the mixture, 100 g, toluene–ethyl acetate 2 : 1).

(1S,4S,5R)-1-((Benzoyloxy)methyl)spiro[bicyclo[3.2.1]octane-8,2′-[1,3]dioxolan]-4-yl benzoate (12). Light oil. [α]²⁰_D = +0 (c 0.312, CHCl₃), [α]²⁰_D = +4.0 (c 0.294, CH₃OH). Found: C, 71.35; H, 6.31. Calc. for C₂₅H₂₆O₆: C, 71.07; H, 6.20%. ¹H NMR (400 MHz, d6-DMSO): δ 1.60–1.76 (m, 5H, H-2a, H-2b, H-3ax, H-6b, H-7b), 1.78–1.92 (m, 2H, H-6a, H-7a), 1.95–2.02 (m, 1H, H-3eq), 2.27 (dd, J_5–4 = 3.1, J_5–6ex = 6.0, 1H, H-5), 3.90–3.99 (m, 4H, −OCH₂CH₂O−), 4.22 and 4.29 (2 × d, 2H, J_gem = 10.9, BzOCH₂−), 5.25 (ddd, J_4–5 = 3.1, J_4–3eq = 5.8, J_4–3ax = 10.6, H-4), 7.50–7.54 (m, 4H, Ph-m1, Ph-m2), 7.63–7.69 (m, 2H, Ph-p1, Ph-p2), 7.94–7.99 (m, 4H, Ph-o1, Ph-o2). ¹³C NMR (100.6 MHz, d6-DMSO): δ 19.28 (C-6), 23.29 (C-3), 28.32 (C-7), 28.94 (C-2), 44.98 (C-5), 45.00 (C-1), 64.20 and 65.31 (−OCH₂CH₂O−), 66.55 (BzOCH₂−), 73.07 (C-4), 115.45 (C-8), 128.92 and 129.00 (C-m1, C-m2), 129.28 (C-o2, C-o1), 129.98 and 130.17 (C-i1 and C-i2), 133.49 and 133.50 (C-p1, C-p2), 165.09 and 165.93 (2 × COO). CI MS, m/z (rel%): 423 (10) [M + H], 301 (100). HRMS: calcd for [M + H]: 423.1808, found: 423.1802.

((1R,2R,5S)-2-Hydroxyspiro[bicyclo[3.2.1]octane-8,2′-[1,3]dioxolan]-5-yl)methyl benzoate (13a). Viscous oil. [α]²⁰_D = +6.3 (c 0.158, CHCl₃). Found: C, 68.19; H, 7.14. Calc. for C₁₈H₂₂O₅: C, 67.91; H, 6.97%. ¹H NMR (400 MHz, d6-DMSO): δ 1.24 (m, 1H, H-6b), 1.45–1.55 (m, 2H, H-2b, H-3b), 1.60–1.64 (m, 2H, H-7a, H-7b), 1.66–1.64 (m, 2H, H-3a, H-6a), 2.00 (dd, J_5–4 = 4.2, J_5–6ex = 6.9, 1H, H-5), 2.06 (m, 1H, H-2a), 3.74 (m, 1H, H-4), 3.84–3.99 (m, 4H, −OCH₂CH₂O−), 4.11 (d, J_OH-4 = 9.2, 1H, 4-OH), 4.18 and 4.24 (2 × d, 2H, J_gem = 10.8, BzOCH₂−), 7.54 (m, 2H, Ph-m), 7.66 (m, 1H, Ph-p), 7.96 (m, 2H, Ph-o). ¹³C NMR (100.6 MHz, d6-DMSO): δ 22.30 (C-6), 26.21 (C-3), 27.40 (C-7), 27.91 (C-2), 44.30 (C-5), 45.06 (C-1), 63.97 and 65.43 (−OCH₂CH₂O−), 66.88 (BzOCH₂−), 72.74 (C-4), 116.37 (C-8), 128.99 (C-m), 129.26 (C-o), 130.02 (C-i), 133.47 (C-p), 165.97 (COO). CI MS, m/z (rel%): 319 (25) [M + H], 301 (100). HRMS: calcd for [M + H]: 319.1545, found: 319.1546.

((1R,2S,5S)-2-Hydroxyspiro[bicyclo[3.2.1]octane-8,2′-[1,3]dioxolan]-5-yl)methyl benzoate (13b). Viscous oil. [α]²⁰_D = +4.9 (c 0.284, CHCl₃). Found: C, 67.68; H, 7.21. Calc. for C₁₈H₂₂O₅: C, 67.91; H, 6.97%. ¹H NMR (400 MHz, d6-DMSO): δ 1.21–1.33 (m, 1H, H-3b), 1.42–1.54 (m, 3H, H-2b, H-6b, H-7b), 1.59–1.75 (m, 4H, H-2a, H-3a, H-6a, H-7a), 1.91 (dd, J_5–4 = 3.0, J_5–6ex = 6.3, 1H, H-5), 3.83–3.89 (m, 5H, −OCH₂CH₂O−, H-4), 4.15 and 4.23 (2 × d, 2H, J_gem = 10.8, BzOCH₂−), 4.45 (d, J_OH-4 = 4.7, 1H, 4-OH), 7.51–7.56 (m, 2H, Ph-m), 7.63–7.68 (m, 1H, Ph-p), 7.93–7.96 (m, 2H, Ph-o). ¹³C NMR (100.6 MHz, d6-DMSO): δ 18.46 (C-6), 26.87 (C-3), 28.56 (C-7), 29.12 (C-2), 44.88 (C-1), 48.01 (C-5), 63.94 and 65.15 (−OCH₂CH₂O−), 66.96 (BzOCH₂−), 68.00 (C-4), 115.89 (C-8), 128.98 (C-m), 129.25 (C-o), 130.04 (C-i), 133.46 (C-p), 165.96 (COO). CI MS, m/z (rel%): 319 (25) [M + H], 301 (100). HRMS: calcd for [M + H]: 319.1545, found: 319.1544.

Recyclation of diol 11 from 12

A freshly prepared sodium methoxide in methanol (prepared from 70 mg of sodium and 27 mL of absolute methanol) was added to a solution of the diol 12 (3.4 g, 8.1 mmol) in absolute methanol (55 mL). The reaction mixture was heated to 60 °C for 12 h and evaporated. The residue was chromatographed on a silica gel column (200 g, ethyl acetate) and 1.54 g (89%) of the recycled diol 11 was obtained. This diol was used again for the monobenzoylation reaction.

((1S,5R)-4-Oxospiro[bicyclo[3.2.1]oct[2]ene-8,2′-[1,3]dioxolan]-1-yl)methyl benzoate (14). A mixture of alcohols 13a and 13b (5.644 g, 17.73 mmol) was dissolved in DMSO (125 mL) and IBX (20.1 g, 71.8 mmol) and p-TsOH (1.013 g, 5.33 mmol) was then added. The reaction mixture was stirred at r.t. for 1 h and then heated to 90 °C for 16 h. A second portion of IBX (2 g) was added and heating was continued for another 3 h. After cooling, the reaction mixture was carefully poured into a satd solution of sodium bicarbonate (400 mL) and this mixture was extracted with ethyl acetate (3 × 500 mL). The combined organic phases were washed with a satd solution of sodium bicarbonate (2 × 600 mL), dried with sodium sulfate and evaporated. The product was purified on a silica gel column (250 g) with diethyl ether as a mobile phase to afford 4.618 g (83%) of the product 14. An analytical sample was obtained by purification on a silica gel column (toluene–ethyl acetate 4 : 1). Viscous oil. [α]²⁰_D = +139.4 (c 0.307, CHCl₃). Found: C, 68.54; H, 5.87. Calc. for C₁₈H₁₈O₅: C, 68.78; H, 5.77%. ¹H NMR (500 MHz, d6-DMSO): δ 1.32–1.39 (m, 1H, H-6en), 1.68–1.74 (m, 1H, H-7en), 1.97–2.03 (m, H-7ex), 2.10–2.17 (m, 1H, H-6ex), 2.77 (ddm, 1H, J_5–3 = 1.7, J_5–6ex = 7.7, 1H, H-5), 3.73–3.98 (m, 4H, −OCH₂CH₂O−), 4.44 and 4.51 (2 × d, 2H, J_gem = 11.1, BzOCH₂−), 6.09 (dd, J_3–5 = 1.7, J_3–2 = 9.9, 1H, H-3), 7.38 (d, J_2–3 = 9.9, 1H, H-2), 7.53–7.56 (m, 2H, Ph-m), 7.65–7.69 (m, 1H, Ph-p), 7.96–7.98 (m, 2H, Ph-o). ¹³C NMR (125.7 MHz, d6-DMSO): δ 20.81 (C-6), 30.76 (C-7), 50.87 (C-1), 57.47 (C-5), 63.67 (BzOCH₂−), 65.15 and 65.40 (−OCH₂CH₂O−), 117.61 (C-8), 128.36 (C-3), 128.97 (C-m), 129.35 (C-o), 129.75 (C-i), 133.60 (C-p), 154.23 (C-2), 165.86 (COO), 200.87 (C-4). ESI MS, m/z (rel%): 337 (100) [M + Na]. HRMS: calcd for [M + Na]: 337.10464, found: 337.10469.

Preparation of compounds 15 and 16

To a solution of the starting material 14 (6.293 g, 20.02 mmol) in methanol (330 mL) at 0 °C, cerium(III) chloride heptahydrate (14.65 g, 35.3 mmol) was added and the reaction mixture was stirred at 0 °C for 1 h. Sodium borohydride (1.05 g, 27.8 mmol) was then added in three portions for 30 minutes, the reaction mixture was stirred at 0 °C for an additional hour, quenched with ice and evaporated. The residue was dissolved in ethyl acetate (600 mL) and washed with water (300 mL). The water phase was extracted with ethyl acetate (600 mL), the combined organic phases were dried with sodium sulfate and evaporated. The residue was chromatographed on silica gel (400 g, toluene–ethyl acetate 4 : 1 → 1 : 1) to afford 3.293 g of 16 (52%) and 2.827 g of 15 (45%) (both colourless oils).

((1S,4S,5R)-4-Hydroxyspiro[bicyclo[3.2.1]oct[2]ene-8,2′-[1,3]dioxolan]-1-yl)methyl benzoate (15). [α]²⁰_D = +121.2 (c 0.307, CHCl₃). Found: C, 68.01; H, 6.57. Calc. for C₁₈H₂₀O₅: C, 68.34; H, 6.37%. ¹H NMR (500 MHz, d6-DMSO): δ 1.51–1.56 (m, 1H, H-6ex), 1.57–1.62 (m, 1H, H-7en), 1.74–1.79 (m, 1H, H-7ex), 1.92 (ddd, J_6en–7ex = 6.6, J_6en–7en = 9.8, J_gem = 13.3, 1H, H-6en), 2.09–2.12 (m, 1H, H-5), 3.80–3.93 (m, 4H, −OCH₂CH₂O−), 4.26 and 4.33 (2 × d, 2H, J_gem = 10.9, BzOCH₂−), 4.48 (bs, 1H, H-4), 4.80 (d, J_OH-4 = 4.5, 1H, OH), 5.49 (dm, J_3–2 = 9.7, 1H, H-3), 5.77 (dd, J_2–4 = 1.7, J_2–3 = 9.7, 1H, H-2), 7.53–7.55 (m, 2H, Ph-m), 7.64–7.67 (m, 1H, Ph-p), 7.94–7.96 (m, 2H, Ph-o). ¹³C NMR (125.7 MHz, d6-DMSO): δ 18.09 (C-6), 33.29 (C-7), 46.62 (C-5), 47.28 (C-1), 64.24 and 65.33 (−OCH₂CH₂O−), 64.63 (BzOCH₂−), 71.01 (H-4), 116.59 (H-8), 128.95 (C-m), 129.29 (C-o), 129.86 (C-3), 129.97 (C-i), 131.21 (C-2), 133.48 (C-p), 165.86 (COO). ESI MS, m/z (rel%): 339 (100) [M + Na]. HRMS: calcd for [M + Na]: 339.12029, found: 339.12024.

((1S,4R,5R)-4-Hydroxyspiro[bicyclo[3.2.1]oct[2]ene-8,2′-[1,3]dioxolan]-1-yl)methyl benzoate (16). [α]²⁰_D = +52.6 (c 0.312, CHCl₃). Found: C, 68.24; H, 6.40. Calc. for C₁₈H₂₀O₅: C, 68.34; H, 6.37%. ¹H NMR (500 MHz, d6-DMSO): δ 1.15 (dddd, J_6en–5 = 1.1, J_6en–7ex = 5.9, J_6en–7en = 9.8, J_gem = 13.4, 1H, H-6en), 1.56–1.61 (m, 1H, H-7en), 1.70–1.76 (m, 1H, H-7ex), 1.83–1.91 (m, 1H, H-6ex), 2.10 (dm, J_5–6ex = 7.9, 1H, H-5), 3.80–3.98 (m, 6H, −OCH₂CH₂O−, H-4, 4-OH), 4.31 and 4.36 (2 × d, 2H, J_gem = 11.0, BzOCH₂−), 5.70 (ddd, J_3–5 = 1.5, J_3–4 = 3.4, J_3–2 = 9.6, 1H, H-3), 5.92 (d, J_2–3 = 9.6, 1H, H-2), 7.52–7.55 (m, 2H, Ph-m), 7.64–7.68 (m, 1H, Ph-p), 7.96–7.98 (m, 2H, Ph-o). ¹³C NMR (125.7 MHz, d6-DMSO): δ 22.30 (C-6), 32.06 (C-7), 44.46 (C-5), 47.40 (C-1), 64.22 and 65.14 (−OCH₂CH₂O−), 64.77 (BzOCH₂−), 74.27 (C-4), 115.40 (C-8), 128.49 (C-3), 128.49 (C-m), 129.28 (C-o), 129.93 (C-i), 133.03 (C-p), 133.46 (C-2), 165.99 (COO). ESI MS, m/z (rel%): 339 (100) [M + Na]. HRMS: calcd for [M + Na]: 339.12029, found: 339.12026.

Recycling of alcohol 15 to ketone 14

To a solution of allyl alcohol 15 (2.088 g, 6.6 mmol) in CH₂Cl₂ (100 mL) manganese(IV) oxide (6.4 g, 10 eq., activated, ∼ 90%) was added in one portion and the reaction mixture was stirred overnight. Solids were removed by filtration on a Celite pad and thoroughly washed with ethyl acetate. The filtrate was evaporated and the crude 15 (quant. yield) was re-used in the Luche reduction. The analytical sample was obtained by silica gel chromatography (toluene–ethyl acetate 4 : 1). NMR spectra match those for 14.

((1S,4R,5R)-4-Hydroxy-8-oxobicyclo[3.2.1]oct-2-en-1-yl)methyl benzoate (17). p-TsOH (2.38 g, 12.49 mmol) was added to a solution of allyl alcohol 16 (3.293 g, 10.41 mmol) in acetone (180 mL) and water (90 mL) and the reaction mixture was heated to reflux for 10 h and then to 50 °C for another 10 h. The reaction mixture was evaporated to half of the original volume and diluted with ethyl acetate (700 mL). The organic phase was washed with water (300 mL) and saturated aq. sodium bicarbonate (300 mL), dried over sodium sulfate and evaporated. The product was purified on a silica gel column (250 g, toluene–ethyl acetate 4 : 1 → 2 : 1) to afford 2.456 g (87%) of 17 as viscous oil. [α]²⁰_D = +15.3 (c 0.326, CHCl₃). Found: C, 70.63; H, 6.27. Calc. for C₁₆H₁₆O₄: C, 70.57; H, 5.92%. ¹H NMR (500 MHz, d6-DMSO): δ 1.50–1.57 (m, 1H, H-6en), 1.86–1.95 (m, 2H, H-7en, H-7ex), 2.03–2.11 (m, 1H, H-6ex), 2.36 (dm, J_5–6ex = 8.4, 1H, H-5), 4.32 and 4.35 (2 × d, 2H, J_gem = 11.3, BzOCH₂−), 4.55 (bs, 1H, H-4), 5.39 (bs, 1H, 4-OH), 5.75 (ddd, J_3–5 = 1.2, J_3–4 = 3.8, J_3–2 = 9.1, 1H, H-3), 5.96 (d, J_2–3 = 9.1, 1H, H-2), 7.51–7.55 (m, 2H, Ph-m), 7.65–7.68 (m, 1H, Ph-p), 7.92–7.95 (m, 2H, Ph-o). ¹³C NMR (125.7 MHz, d6-DMSO): δ 19.35 (C-6), 29.16 (C-7), 49.88 (C-1), 50.10 (C-5), 63.75 (BzOCH₂−), 79.92 (C-4), 129.01 (C-m), 129.39 (C-o), 129.56 (C-3), 129.74 (C-i), 133.55 and 133.66 (C-p and C-2), 165.86 (COO), 212.74 (C-8). ESI MS, m/z (rel%): 295 (100) [M + Na]. HRMS: calcd for [M + Na]: 295.09408, found: 295.09416.

((1S,4R,5R,8S)-4,8-Dihydroxybicyclo[3.2.1]oct-2-en-1-yl)methyl benzoate (18). To an ice-cooled solution of the keto derivative 17 (2.456 g, 9.02 mmol) in a mixture of acetonitrile (170 mL) and acetic acid (5.2 mL), sodium triacetoxyborohydride (2.87 g, 13.5 mmol) was added in four portions for 30 minutes. The reaction mixture was allowed to warm to r.t. and stirring was continued for 12 h. The reaction mixture was quenched with methanol and evaporated. The residue was dissolved in methanol and adsorbed on silica gel. Chromatography on a silica gel column (200 g) in ethyl acetate afforded 2.173 g (88%) of the product 18 as a white solid. M.p. 130–131 °C. [α]²⁰_D = −7.1 (c 0.320, CHCl₃). Found: C, 69.90; H, 6.60. Calc. for C₁₆H₁₈O₄: C, 70.06; H, 6.61%. ¹H NMR (500 MHz, d6-DMSO): δ 1.09–1.15 (m, 1H, H-6en), 1.43–1.48 (m, 1H, H-7en), 1.63–1.70 (m, 1H, H-7ex), 1.88–1.96 (m, 1H, H-6ex), 2.12 (dm, J_5–6ex = 8.0, 1H, H-5), 3.86–3.89 (m, 1H, H-4), 3.99 (d, J_8-OH = 4.0, 1H, H-8), 4.29 and 4.33 (2 × d, 2H, J_gem = 10.6, BzOCH₂−), 4.85 (d, J_OH-8 = 4.0, 1H, 8-OH), 4.94 (d, J_OH-4 = 5.2, 1H, 4-OH), 5.52 (ddd, J_3–5 = 1.6, J_3–4 = 3.9, J_3–2 = 9.4, 1H, H-3), 5.85 (d, J_2–3 = 9.4, 1H, H-2), 7.51–7.55 (m, 2H, Ph-m), 7.64–7.68 (m, 1H, Ph-p), 7.95–7.97 (m, 2H, Ph-o). ¹³C NMR (125.7 MHz, d6-DMSO): δ 23.65 (C-6), 31.33 (C-7), 48.77 (C-5), 49.75 (C-1), 66.44 (BzOCH₂−), 72.08 (C-8), 73.25 (C-4), 128.12 (C-3), 128.93 (C-m), 129.35 (C-o), 130.21 (C-i), 133.46 (C-p), 135.73 (C-2), 166.07 (COO). ESI MS, m/z (rel%): 297 (100) [M + Na]. HRMS: calcd for [M + Na]: 297.10973, found: 297.10972.

((1S,4R,5S,8S)-8-(Benzoyloxy)-4-((tert-butyldimethylsilyl)oxy)bicyclo[3.2.1]oct-2-en-1-yl)methyl benzoate (19). To an ice-cooled solution of diol 18 (2.419, 8.82 mmol) and imidazole (901 mg, 13.23 mmol) in CH₂Cl₂ (53 mL) was added TBDMSCl (total amount 1.6 g, 10.6 mmol) in two portions for 30 minutes and the reaction mixture was stirred at 0 °C for 16 h. Volatiles were evaporated, the residue was dissolved in ethyl acetate (700 mL) and the organic phase was washed with water (2 × 300 mL), dried with sodium sulfate, evaporated and co-evaporated with benzene (200 mL). The crude intermediate was dissolved in pyridine (50 mL) and then DMAP (catalytic amount) and benzoylchloride (2.05 mL 17.6 mmol) were added. The reaction mixture was left in the dark for 18 h. The reaction was then quenched with water and pyridine was evaporated. The residue was dissolved in ethyl acetate (700 mL) and washed with water (2 × 300 mL) and saturated aq. sodium bicarbonate (2 × 300 mL), dried with sodium sulfate and evaporated. The product was isolated by column chromatography on silica gel (250 g, hexanes–ethyl acetate 20 : 1) affording 3.691 g (85% over two steps) of 19 as an oil. [α]²⁰_D = +54.4 (c 0.375, CHCl₃). Found: C, 70.99; H, 7.36. Calc. for C₂₉H₃₆O₅Si: C, 70.70; H, 7.37%. ¹H NMR (500 MHz, d6-DMSO): δ 0.07 and 0.08 (2 × s, 2 × 3H, 2 × CH₃), 0.88 (s, 9H, tBu), 1.33–1.39 (m, 1H, H-6en), 1.67–1.73 (m, 1H, H-7en), 1.95–2.01 (m, 1H, H-7ex), 2.04–2.12 (m, 1H, H-6ex), 2.38 (dm, J_5–6ex = 7.9, 1H, H-5), 4.17–4.19 (m, 1H, H-4), 4.34 and 4.41 (2 × d, 2H, J_gem = 11.1, BzOCH₂−), 5.46 (bs, 1H, H-8), 5.64 (ddd, J_3–5 = 1.5, J_3–4 = 4.1, J_3–2 = 9.4, 1H, H-3), 5.96 (d, J_2–3 = 9.4, 1H, H-2), 7.45–7.52 (m, 4H, Ph-m1, Ph-m2), 7.61–7.66 (m, 2H, Ph-p1, Ph-p2), 7.87–7.89 (m, 2H, Ph-o2), 7.95–7.97 (m, 2H, Ph-o1). ¹³C NMR (125.7 MHz, d6-DMSO): δ −4.30 and −4.55 (2 × CH₃), 17.99 (C(CH₃)₃), 22.92 (C-6), 25.91 (tBu), 31.41 (C-7), 47.00 (C-5), 49.19 (C-1), 65.46 (BzOCH₂−), 73.87 (C-4), 77.11 (C-8), 127.98 (C-3), 128.87 and 128.96 (C-m1, C-m2), 129.27 (C-o2), 129.44 (C-o1), 129.81 and 130.02 (C-i1 and C-i2), 133.54 (C-p1, C-p2), 135.02 (C-2), 164.93 (COO-1), 165.70 (COO-2). ESI MS, m/z (rel%): 515 (100) [M + Na]. HRMS: calcd for [M + Na]: 515.22242, found: 515.22244.

((1S,4R,5R,8S)-8-(Benzoyloxy)-4-hydroxybicyclo[3.2.1]oct-2-en-1-yl)methyl benzoate (20). Silyl derivative 19 (2.910 g, 5.91 mmol) was dissolved in a mixture of THF (65 mL) and acetic acid (1.2 mL) under an argon atmosphere. The reaction mixture was treated with TBAF (8.9 mL, 1 M solution in THF) at r.t. After 30 minutes the reaction mixture was heated to 60 °C for 24 h and then evaporated. The residue was dissolved in ethyl acetate (700 mL) and washed with water (300 mL). The organic phase was dried with sodium sulfate and evaporated. Chromatography (silica gel 250 g, toluene–ethyl acetate 3 : 1) of the residue afforded 2.05 g (92%) of 20 as a viscous oil. [α]²⁰_D = +120.60 (c 0.329, CHCl₃). Found: C, 72.72; H, 6.10. Calc. for C₂₃H₂₂O₅: C, 73.00; H; 5.86%. ¹H NMR (500 MHz, d6-DMSO): δ 1.31–1.38 (m, 1H, H-6en), 1.69–1.74 (m, 1H, H-7en), 1.93–1.99 (m, 1H, H-7ex), 2.04–2.12 (m, 1H, H-6ex), 2.39 (d, J_5–6ex = 8.2, 1H, H-5), 4.00–4.03 (m, 1H, H-4), 4.32 and 4.38 (2 × d, 2H, J_gem = 11.1, BzOCH₂−), 5.24 (d, 1H, 4-OH), 5.48 (bs, 1H, H-8), 5.67 (ddd, J_3–5 = 1.5, J_3–4 = 3.9, J_3–2 = 9.5, 1H, H-3), 5.96 (d, J_2–3 = 9.5, 1H, H-2), 7.48–7.53 (m, 4H, Ph-m1, Ph-m2), 7.62–7.67 (m, 2H, Ph-p1, Ph-p2), 7.89–7.91 (m, 2H, Ph-o2), 7.95–7.97 (m, 2H, Ph-o1). ¹³C NMR (125.7 MHz, d6-DMSO): δ 23.46 (C-6), 31.79 (C-7), 46.88 (C-5), 49.18 (C-1), 65.51 (BzOCH₂−), 72.86 (C-4), 77.22 (C-8), 128.63 (C-3), 128.89 and 128.97 (C-m1, C-m2), 129.31 (C-o2), 129.38 (C-o1), 129.76 and 130.04 (C-i1 and C-i2), 133.52 (C-p1, C-p2), 134.67 (C-2), 165.05 (COO-1), 165.72 (COO-2). ESI MS, m/z (rel%): 401 (100) [M + Na]. HRMS: calcd for [M + Na]: 401.13594, found: 401.13608.

Preparation of compounds 22a and 22

A solution of PPh₃ (2.99 g, 11.4 mmol) and N-chlorosuccinimide (1.53 g, 11.45 mmol) in CH₂Cl₂ (32 mL) was stirred at 0 °C for 30 minutes. A solution of hydroxy derivative 20 (2.155 g, 5.65 mmol) in CH₂Cl₂ (32 mL + 5 mL for rinsing the flask) was then added dropwise for 30 minutes. The reaction mixture was stirred at 0 °C for 2 h and then treated with methanol (5 mL) and evaporated. The residue was chromatographed on a silica gel column (250 g, hexanes–ethyl acetate 10 : 1) and the isolated intermediate was immediately used in the following step. Chloro derivative 21 was dissolved in DMF (44 mL) and treated with sodium azide (1.836 g, 28.3 mmol) at 65 °C for 12 h. Volatiles were evaporated, the residue was dissolved in ethyl acetate (350 mL) and washed with water (200 mL). The organic phase was dried with sodium sulfate, evaporated and the crude product was chromatographed on a silica gel column (250 g, hexanes–ethyl acetate 20 : 1 → 10 : 1) to afford 22a (505 mg, 22% over 2 steps) and 22 (1.64 g, 72% over 2 steps, both were oils).

(1R,4S,5S,8S)-4-Azido-5-((benzoyloxy)methyl)bicyclo[3.2.1]oct-2-en-8-yl benzoate (22a). ¹H NMR (500 MHz, d6-DMSO): δ 1.69–1.76 (m, 2H, H-7en, H-6ex), 2.11–2.19 (m, 2H, H-6en, H-7ex), 2.76–2.80 (m, 1H, H-1), 4.44 (d, 1H, J_4–3 = 4.2, H-4), 4.47 and 4.52 (2 × d, 2H, J_gem = 11.0, BzOCH₂−), 5.19 (s, 1H, H-8), 5.77 (dd, J_3–4 = 4.2, J_3–2 = 9.3, 1H, H-3), 6.28 (dd, J_2–1 = 6.9, J_2–3 = 9.3, 1H, H-2), 7.49–7.54 (m, 4H, Ph-m1, Ph-m2), 7.64–7.69 (m, 2H, Ph-p1, Ph-p2), 7.97–8.00 (m, 4H, Ph-o2, Ph-o1). ¹³C NMR (125.7 MHz, d6-DMSO): δ 29.48 (C-6), 29.92 (C-7), 41.26 (C-1), 50.49 (C-5), 66.14 (C-4), 66.29 (BzOCH₂−), 77.69 (C-8), 122.20 (C-3), 128.85 and 128.94 (C-m1, C-m2), 129.34 and 129.42 (C-o1, C-o2), 129.48 and 129.57 (C-i1 and C-i2), 133.54 and 133.73 (C-p1, C-p2), 136.22 (C-2), 165.20 (8-COO), 165.63 (−CH₂OCOO). ESI MS, m/z (rel%): 426 (100) [M + Na]. HRMS: calcd for [M + Na]: 426.14243, found: 426.14233.

(1S,4R,5R,8S)-4-Azido-1-((benzoyloxy)methyl)bicyclo[3.2.1]oct-2-en-8-yl benzoate (22). [α]²⁰_D = −10.2 (c 0.275, CHCl₃). Found: C, 68.45; H, 5.30; N, 10.11. Calc. for C₂₃H₂₁N₃O₄: C, 68.47; H, 5.25; N, 10.42%. ¹H NMR (500 MHz, d6-CDCl₃): δ 1.52 (ddd, J_6en–7ex = 6.2, J_6en–7en = 9.2, J_gem = 14.0, 1H, H-6en), 1.89–1.95 (m, 1H, H-7en), 2.04–2.11 (m, 1H, H-7ex), 2.21–2.29 (m, 1H, H-6en), 2.73 (dm, J_5–6ex = 8.1, 1H, H-5), 3.99 (t, J_4–5 = 3.3, 1H, H-4), 4.39 and 4.56 (2 × d, 2H, J_gem = 11.2, BzOCH₂−), 5.49 (s, 1H, H-8), 5.73 (ddd, J_3–5 = 1.6, J_3–4 = 4.1, J_3–2 = 9.5, 1H, H-3), 6.20 (d, 1H, J_2–3 = 9.5, 1H, H-2), 7.39–7.45 (m, 4H, Ph-m1, Ph-m2), 7.52–7.58 (m, 2H, Ph-p1, Ph-p2), 7.99–8.02 (m, 4H, Ph-o2, Ph-o1). ¹³C NMR (125.7 MHz, CDCl₃): δ 24.96 (C-6), 32.73 (C-7), 44.74 (C-5), 49.15 (C-1), 64.81 (C-4), 65.17 (BzOCH₂), 76.76 (C-8), 122.80 (C-3), 128.39 and 128.44 (C-m1, C-m2), 129.56 and 129.64 (C-o1, C-o2), 129.75 and 129.99 (C-i1 and C-i2), 133.07 and 133.16 (C-p1, C-p2), 138.46 (C-2), 164.33 (COO-1), 165.40 (COO-2). ESI MS, m/z (rel%): 426 (100) [M + Na]. HRMS: calcd for [M + Na]: 426.14243, found: 426.14229.

Allylic rearrangement of 22a to 22

A solution of compound 22a (505 mg, 1.25 mmol) in acetonitrile (35 mL) was heated to 95 °C for 24 h. The reaction mixture was evaporated and the residue was chromatographed (100 g, hexanes–ethyl acetate 10 : 1) to afford 241 mg (48%) of 22.

(1S,4R,5R,8S)-4-Amino-1-(hydroxymethyl)bicyclo[3.2.1]oct-2-en-8-ol (23). Azido derivative 22 (1.64 g, 4.06 mmol) was dissolved in dry THF (20 mL, argon atmosphere) and then PPh₃ (1.42 g, 5.41 mmol) was added. The reaction mixture was stirred for 20 h, then water (1.23 mL) was added and stirring was continued for another 20 h. The reaction mixture was evaporated and re-dissolved in EtOH–H₂O (18 mL, 1 : 1). Potassium hydroxide (1.2 g, 21.4 mmol) was added and the reaction mixture was heated to reflux for 5 h, neutralized with aq. HCl and purified on a DOWEX 50 (100 mL, H⁺ cycle). The column was washed with water (400 mL), methanol (400 mL) and the product was then eluted with aq. NH₃–MeOH (1 : 4, v/v). Fractions containing the product were evaporated and the oily residue was converted to hydrochloride salt with hydrogen chloride in dioxane (2 M) (659 mg, 79%, slightly hygroscopic yellowish solid). [α]²⁰_D = −51.4 (c 0.292, CH₃OH). Found: C, 51.21; H, 7.70; N, 6.23. Calc. for C₉H₁₆ClNO₂·1/3H₂O: C, 51.06; H, 7.94; N, 6.62%. ¹H NMR (500 MHz, d6-DMSO): δ 1.26 (ddd, J_6en–7ex = 5.9, J_6en–7en = 9.1, J_gem = 13.7, 1H, H-6en), 1.37–1.43 (m, 1H, H-7en), 1.52–1.59 (m, 1H, H-7ex), 1.98–2.06 (m, 1H, H-6ex), 2.24 (d, J_5–6ex = 8.0, 1H, H-5), 3.41 (d, J_gem = 10.7, 1H, CHbOH), 3.52 (m, 2H, H-4, CHaOH), 4.00 (bs, 1H, H-8), 4.62 and 4.89 (2 × bs, 2H, 8-OH, CH₂OH), 5.48 (dd, J_3–5 = 1.7, J_3–4 = 3.6, J_3–2 = 9.5, 1H, H-3), 6.13 (dd, J_2–4 = 0.8, J_2–3 = 9.5, 1H, H-2), 8.20 (bs, 3H, NH₃⁺). ¹³C NMR (125.7 MHz, d6-DMSO): δ 25.78 (C-6), 31.86 (C-7), 43.97 (C-5), 51.88 (C-1), 55.09 (C-4), 62.24 (CH₂OH), 71.21 (C-8), 120.68 (C-3), 142.49 (C-2). CI MS, m/z (rel%): 152 (100) [M + H-H₂O]. HRMS: calcd for [M + H]: 171.1181, found: 170.1176.

(1S,4R,5R,8S)-4-(6-Chloro-9H-purin-9-yl)-1-(hydroxymethyl)bicyclo[3.2.1]oct-2-en-8-ol (24). A mixture of amine 23 (1 g, 4.9 mmol), 4,6-dichloro-5-formamido-pyrimidine (1.56 g, 7.35 mmol, prepared according to published procedure²⁶) and DIPEA (2.9 mL, 14.7 mmol) in n-BuOH (25 mL) was heated in a sealed microwave reactor for 2 h at 140 °C. After evaporation the residue was chromatographed on a silica gel column (400 g) in ethyl acetate → ethyl acetate–toluene–acetone–ethanol (17 : 4 : 3 : 1) to afford 24 (631 mg, 42%). The analytical sample was crystalized from ethanol (white solid). M.p. 176.5–177 °C (decomposition, EtOH). [α]²⁰_D = −18.6 (c 0.297, CH₃OH). Found: C, 54.50; H, 4.91; Cl, 11.30; N, 17.87. Calc. for C₁₄H₁₅ClN₄O₂: C, 54.82; H, 4.93; Cl, 11.56; N, 18.26%. ¹H NMR (500 MHz, d6-DMSO): δ 1.46–1.53 (m, 1H, H-6en), 1.54–1.60 (m, 1H, H-7en), 1.65–1.72 (m, 1H, H-7ex), 2.06–2.13 (m, 1H, H-6ex), 2.42 (dm, J_5–6ex = 7.8, 1H, H-5), 3.51 (dd, J_CH–OH = 5.3, J_gem = 10.5, 1H, CHbOH), 3.63 (dd, J_CH–OH = 5.3, J_gem = 10.5, 1H, CHaOH), 3.74 (d, J_8-OH = 3.6, 1H, H-8), 4.53 (t, J_OH–CH2 = 5.3, 1H, CH₂OH), 4.63 (d, J_OH-8 = 3.6, 1H, 8-OH), 5.10–5.12 (m, 1H, H-4), 5.76 (ddd, J_3–5 = 1.7, J_3–4 = 3.9, J_3–2 = 9.4, 1H, H-3), 6.40 (dd, J_2–4 = 1.2, J_2–3 = 9.4, 1H, H-2), 8.49 (s, 1H, H-8′), 8.83 (s, 1H, H-2′). ¹³C NMR (125.7 MHz, d6-DMSO): δ 25.10 (C-6), 32.31 (C-7), 46.26 (C-5), 51.70 (C-1), 59.74 (C-4), 62.18 (CH₂OH), 71.81 (C-8), 119.57 (C-3), 131.47 (C-5′), 143.33 (C-2), 145.84 (C-8′), 149.32 (C-6′), 151.48 (C-4′), 151.67 (C-2′). ESI MS, m/z (rel%): 329/331 (100/33) [M + Na]. HRMS: calcd for [M + Na]: 329.07757, found: 329.07771.

(1S,4R,5R,8S)-4-(6-Amino-9H-purin-9-yl)-1-(hydroxymethyl)bicyclo[3.2.1]oct-2-en-8-ol (25). A solution of chloropurine derivative 24 (540 mg, 1.76 mmol) was dissolved in ethanolic ammonia (3.5 M, 6 mL) heated in a sealed microwave reactor at 140 °C for 1 h. The reaction mixture was evaporated and chromatographed on a silica gel column (200 g) in ethyl acetate → ethyl acetate–acetone–ethanol–H₂O (19 : 3 : 1.8 : 1.2) to afford 433 mg (86%) of the product 25. The analytical sample was crystallized from ethanol (white solid).

Enantiomeric purity was determined by chiral HPLC on a Chirapak IA (Daicel) column with heptane–ethanol 2 : 1 + 0.1% Et₂NH as an eluent (Fig. S4 and S5†).

M.p. 158.5–159.5 °C (EtOH). [α]²⁰_D = −50.1 (c 0.154, CH₃OH). Found: C, 53.48; H, 6.24; N, 22.14. Calc. for C₁₄H₁₇N₅O₂·1.5H₂O: C, 53.49; H, 6.41; N, 22.28%. ¹H NMR (500 MHz, d6-DMSO): δ 1.41–1.48 (m, 1H, H-6en), 1.51–1.57 (m, 1H, H-7en), 1.63–1.70 (m, 1H, H-7ex), 2.02–2.10 (m, 1H, H-6ex), 2.37 (dm, J_5–6ex = 7.9, 1H, H-5), 3.49 (dd, J_CH–OH = 5.5, J_gem = 10.5, 1H, CHbOH), 3.62 (dd, J_CH–OH = 5.5, J_gem = 10.5, 1H, CHaOH), 3.73 (d, J_8-OH = 3.5, 1H, H-8), 4.53 (t, J_OH–CH2 = 5.3, 1H, CH₂OH), 4.63 (d, J_OH-8 = 3.5, 1H, 8-OH), 4.91–4.93 (m, 1H, H-4), 5.71 (ddd, J_3–5 = 1.6, J_3–4 = 3.9, J_3–2 = 9.5, 1H, H-3), 6.40 (dd, J_2–4 = 1.1, J_2–3 = 9.5, 1H, H-2), 7.27 (bs, 2H, NH₂), 7.90 (s, 1H, H-8′), 8.17 (s, 1H, H-2′). ¹³C NMR (125.7 MHz, d6-DMSO): δ 25.20 (C-6), 32.41 (C-7), 46.46 (C-5), 51.77 (C-1), 58.82 (C-4), 62.28 (CH₂OH), 71.69 (C-8), 119.39 (C-5′), 120.42 (C-3), 139.06 (C-8′), 142.64 (C-2), 149.18 (C-4′), 151.68 (C-2′), 156.30 (C-6′). ESI MS, m/z (rel%): 310 (100) [M + Na]. HRMS: calcd for [M + H]: 288.14550, found: 288.14557; calcd for [M + Na]: 310.12745, found: 310.12747.

(1S,4R,5R,8S)-4-(6-Amino-9H-purin-9-yl)-1-(hydroxymethyl)-bicyclo[3.2.1]octan-8-ol (26). To a solution of nucleoside 25 (500 mg, 1.74 mmol) in methanol (50 mL) was added Pd(OH)₂/C (200 mg) and the reaction mixture was hydrogenated in a steel autoclave (10 bars of hydrogen) at 50 °C for 24 h. Solids were filtered off on a pad of Celite and the residue was chromatographed on a silica gel column (200 g, ethyl acetate → ethyl acetate–acetone–ethanol–H₂O (19 : 3 : 1.8 : 1.2)) to afford 450 mg (89%) of the product 26. The analytical sample was crystalized from ethanol (white solid). M.p. 241.5–242.5 °C (EtOH). [α]²⁰_D = +54.5 (c 0.301, CH₃OH). Found: C, 56.33; H, 6.46; N; 23.23. Calc. for C₁₄H₁₉N₅O₂·0.5H₂O: C, 56.36; H, 6.76; N, 23.47%. ¹H NMR (600 MHz, d6-DMSO): δ 1.40–1.45 (m, 1H, H-7en), 1.52–1.58 (m, 3H, H-2eq, H-6en, H-7ex), 1.92–2.02 (m, 2H, H-2ax, H-6ex), 2.07–2.17 (m, 2H, H-3), 2.65 (dd, J_5–4 = 3.9, J_5–6ex = 7.0, 1H, H-5), 3.32 (dd, J_CH–OH = 5.0, J_gem = 10.5, 1H, CHbOH), 3.38 (d, J_8-OH = 3.5, 1H, H-8), 3.53 (dd, J_CH–OH = 5.0, J_gem = 10.5, 1H, CHaOH), 4.32 (t, J_OH–CH2 = 5.0, 1H, CH₂OH), 4.42 (d, J_OH-8 = 3.5, 1H, 8-OH), 4.52–4.54 (m, 1H, H-4), 7.21 (bs, 2H, NH₂), 8.14 (s, 1H, H-2′), 8.15 (s, 1H, H-8′). ¹³C NMR (150.92 MHz, d6-DMSO): δ 21.51 (C-3), 25.63 (C-6), 28.26 (C-7), 31.75 (C-2), 47.10 (C-5), 49.54 (C-1), 56.99 (C-4), 64.92 (CH₂OH), 74.66 (C-8), 119.12 (C-5′), 138.98 (C-8′), 149.81 (C-4′), 152.44 (C-2′), 156.21 (C-6′). ESI MS, m/z (rel%): 312 (100) [M + Na]. HRMS: calcd for [M + H]: 290.16115, found: 290.16124; calcd for [M + Na]: 312.14310, found: 312.14315.

N-(9-((1R,2R,5S,8S)-8-Hydroxy-5-(hydroxymethyl)-bicyclo[3.2.1]oct-3-en-2-yl)-9H-purin-6-yl)benzamide (27). Nucleoside 25 (550 mg, 1.91 mmol) was co-evaporated with pyridine (2 × 15 mL), dissolved in pyridine (24 mL), cooled to 0 °C and then TMSCl (1.22 mL, 9.6 mmol) was added dropwise for 10 minutes. The reaction mixture was stirred at 0 °C for 1 h and then benzoyl chloride (1.11 mL, 9.6 mmol) was slowly added and the reaction mixture was left at 0 °C for 1 h and at r.t. for another 12 h. The mixture was cooled to 0 °C again, quenched with water (3.5 mL), and after 15 minutes aq. ammonia (6.4 mL, 25%) was added and after further 15 minutes the reaction mixture was evaporated. The residue was re-dissolved in methanol (17 mL) and aq. ammonia (12 mL, 25%) and after 1 h at r.t. evaporated. The residue was chromatographed on a silica gel column (100 g) in ethyl acetate → ethyl acetate–acetone–ethanol–H₂O (21 : 3 : 0.6 : 0.4) to afford 27 (464 mg, 62%) as a yellowish foam. [α]²⁰_D = −86.1 (c 0.296, CH₃OH). Found: C, 63.40; H, 5.46; N, 17.38. Calc. for C₂₁H₂₁N₅O₃·1/3H₂O: C, 63.46; H, 5.50; N, 17.62%. ¹H NMR (600 MHz, d6-DMSO): δ 1.48–1.54 (m, 1H, H-6en), 1.55–1.60 (m, 1H, H-7en), 1.66–1.73 (m, 1H, H-7ex), 2.07–2.15 (m, 1H, H-6ex), 2.44 (dm, J_5–6ex = 8.0, 1H, H-5), 3.51 (dd, J_CH–OH = 5.1, J_gem = 10.5, 1H, CHbOH), 3.64 (dd, J_CH–OH = 5.1, J_gem = 10.5, 1H, CHaOH), 3.77 (d, J_8-OH = 3.5, 1H, H-8), 4.54 (t, J_OH–CH2 = 5.1, 1H, CH₂OH), 4.69 (d, J_OH-8 = 3.5, 1H, 8-OH), 5.09–5.11 (m, 1H, H-4), 5.77 (ddd, J_3–5 = 1.6, J_3–4 = 3.9, J_3–2 = 9.5, 1H, H-3), 6.39 (dd, J_2–4 = 1.1, J_2–3 = 9.5, 1H, H-2), 7.53–7.57 (m, 2H, Ph-m), 7.63–7.66 (m, 1H, Ph-p), 8.04–8.06 (m, 2H, Ph-o), 8.24 (s, 1H, H-8′), 8.77 (s, 1H, H-2′), 11.21 (bs, 1H, NH). ¹³C NMR (150.92 MHz, d6-DMSO): δ 25.16 (C-6), 32.37 (C-7), 46.45 (C-5), 51.72 (C-1), 59.18 (C-4), 62.23 (CH₂OH), 71.82 (C-8), 119.96 (C-3), 126.09 (C-5′), 128.61 (C-m,o), 132.55 (C-p), 133.62 (C-i), 142.87 (C-8′), 143.04 (C-2), 150.48 (C-6′), 151.53 (C-2′), 151.98 (C-4′), 165.87 (COO). ESI MS, m/z (rel%): 414 (100) [M + Na]. HRMS: calcd for [M + Na]: 414.15366, found: 414.15359.

N-(9-((1R,2R,5S,8S)-5-((Bis(4-methoxyphenyl)-(phenyl)methoxy)methyl)-8-hydroxybicyclo[3.2.1]oct-3-en-2-yl)-9H-purin-6-yl)benzamide (28). Compound 27 (311 mg, 0.79 mmol) was co-evaporated with pyridine (2 × 7 mL) and then dissolved in pyridine (6 mL) and cooled to 0 °C. DMTrCl (404 mg, 1.19 mmol) was added in one portion and the reaction mixture was slowly warmed to r.t. and then stirred for 48 h. The reaction mixture was evaporated and the residue was dissolved in ethyl acetate (300 mL), washed with a satd solution of sodium bicarbonate (2 × 100 mL) and brine (100 mL), dried with sodium sulfate and evaporated. The residue was chromatographed on a silica gel column (150 g – deactivated with triethylamine, toluene–ethyl acetate 1 : 3) to afford 358 mg (65%) of the product 28 as a foam (contains some inseparable impurities according ¹³C NMR, the compound was pure enough for the next step). [α]²⁰_D = −8.0 (c 0.313, CH₃OH). Found: C, 72.43; H, 5.83; N, 9.71. Calc. for C₄₂H₃₉N₅O₅: C, 72.71; H, 5.67; N, 10.09%. ¹H NMR (500 MHz, d6-DMSO): δ 1.50–1.56 (m, 1H, H-6en), 1.70 (m, 2H, H-7en, H-7ex), 2.08–2.15 (m, 1H, H-6ex), 2.48 (bs, 1H, H-5), 3.06 and 3.29 (2 × d, J_gem = 8.4, 2H, OCH₂), 3.74 (2 × s, 2 × 3H, 2 × OCH₃), 3.88 (bs, 1H, H-8), 4.76 (d, J_8-OH = 3.4, 1H, H-8), 5.13–5.15 (m, 1H, H-4), 5.82 (ddd, J_3–5 = 1.6, J_3–4 = 3.9, J_3–2 = 9.4, 1H, H-3), 6.31 (dd, J_2–4 = 1.1, J_2–3 = 9.4, 1H, H-2), 6.89–6.92 (m, 4H, H-3′′), 7.21–7.24 (m, 1H, 4′′′), 7.28–7.30 (m, 4H, H-2′′), 7.31–7.34 (m, 2H, H-3′′′), 7.42–7.44 (m, 2H, H-2′′′), 7.54–7.57 (m, 2H, Bz-m), 7.63–7.66 (m, 1H, Bz-p), 8.04–8.07 (m, 2H, Bz-o), 8.28 (s, 1H, H-8′), 8.79 (s, 1H, H-2′), 11.25 (bs, 1H, NH). ¹³C NMR (125.7 MHz, d6-DMSO): δ 24.99 (C-6), 32.99 (C-7), 46.55 (C-5), 50.48 (C-1), 55.19 and 55.20 (2 × OCH₃), 59.20 (C-4), 64.87 (OCH₂), 72.14 (C-8), 85.10 (Ph₃CO−), 113.30 and 113.31 (2 × C-3′′), 120.00 (C-3), 126.17 (C-5′), 126.75 (C-4′′′), 127.92 and 127.96 (C-2′′′, C-3′′′), 128.64 and 128.66 (Bz-o, Bz-m), 129.95 and 129.99 (2 × C-2′′), 132.60 (Bz-p), 133.61 (Bz-i), 135.99 and 136.19 (2 × C-1′′), 142.68 and 142.75 (C-2 and C-8′), 145.51 (C-1′′′), 150.55 (C-6′), 151.61 (C-2′), 152.04 (C-4′), 158.16 and 158.17 (C-4′′), 165.93 (COO). ESI MS, m/z (rel%): 716 (100) [M + Na]. HRMS: calcd for [M + Na]: 716.28434, found: 716.28429.

(1S,4R,5R,8S)-4-(6-Benzamido-9H-purin-9-yl)-1-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)bicyclo[3.2.1]oct-2-en-8-yl (2-cyanoethyl) diisopropylphosphoramidite (29). Compound 28 (358 mg, 0.52 mmol) and DIPEA (0.353 mL, 2.05 mmol) were dissolved in dry THF (5 mL) and the flask was rinsed several times with argon. 2-Cyanoethyl N,N-diisopropyl-chlorophosphoramidite (0.21 mL, 0.94 mmol) was added dropwise at r.t. for 15 minutes. The reaction mixture was stirred at r.t. for 3.5 h and then poured into the mixture of a satd solution of sodium bicarbonate with ice (100 mL). The water phase was extracted with ethyl acetate (2 × 200 mL) and the combined organic phases were dried with sodium sulfate and evaporated. The residue was co-evaporated with benzene (2 × 50 mL) and then chromatographed (100 g – deactivated with triethylamine, toluene–ethyl acetate 1 : 1 to afford 297 mg (72%) of the product 29 as a white foam. ³¹P{¹H} NMR (202 MHz, d6-DMSO): 145.73, 145.21. ESI MS, m/z (rel%): 916 (100) [M + Na]. HRMS: calcd for [M + H]: 894.41025, found: 894.41126; calcd for [M + Na]: 916.39219, found: 916.39245.

N′-(9-((1R,2R,5S,8S)-5-((Bis(4-methoxyphenyl)-(phenyl)methoxy)methyl)-8-hydroxybicyclo[3.2.1]octan-2-yl)-9H-purin-6-yl)-N,N-dibutylformimidamide (30). Saturated nucleoside 26 (430 mg, 1.49 mmol) was suspended in methanol (10 mL), dimethylacetal-N,N-dibutylformamide (0.87 mL, 3.73 mmol) was then added in three portions and the reaction mixture was allowed to stir at r.t. for 11 h. A chromatography on a silica gel column (150 g, ethyl acetate → ethyl acetate–methanol 6 : 1) afforded a foam, which was directly used for the tritylation. The foam was co-evaporated with pyridine (2 × 10 mL), then dissolved in pyridine (10 mL) and cooled to 0 °C. DMTrCl (636 mg, 1.88 mmol) was added in one portion, the reaction mixture was slowly warmed to r.t. and then stirred for 48 h. Volatiles were evaporated and the residue was dissolved in ethyl acetate (300 mL), washed with a satd solution of sodium bicarbonate (2 × 150 mL) and brine (150 mL), dried with sodium sulfate, evaporated and chromatographed on a silica gel column (200 g – deactivated with triethylamine, ethyl acetate–acetone 10 : 1) to afford 727 mg (83%) of 30 as a white foam. [α]²⁰_D = −18.5 (c 0.313, CH₃OH). Found: C, 72.01; H, 7.40; N, 11.17. Calc. for C₄₄H₅₄N₆O₄: C, 72.30; H, 7.45; N, 11.50%. ¹H NMR (500 MHz, d6-DMSO): δ 0.93 (q, J_4–3 = 7.5, 6H, 2 × CH₃), 1.28–1.37 (m, 4H, H-4), 1.46–1.51 (m, 1H, H-7′′ex), 1.55–1.65 (m, 6H, H-2, H-6′′en, H-7′′en), 1.74–1.78 (m, 1H, H-2′′a), 1.94–2.00 (m, 1H, H-6′′en), 2.04–2.11 (m, 1H, H-2′′b), 2.15–2.20 (m, 2H, H-3′′ax, H-3′′eq), 2.71 (dd, J_{5′′–6′′ex} = 7.3, J_{5′′–4′′} = 3.8, H-5′′), 2.90 and 3.16 (2 × d, J_gem = 8.4, 2H, OCH₂), 3.40 (d, J_8′′OH = 3.9, 1H, H-8′′), 3.42–3.45 and 3.55–3.64 (2 × m, 2 × 2H, H-2), 3.73 (2 × s, 2 × 3H, 2 × OCH₃), 4.59–4.62 (m, 1H, H-4′′), 6.86–6.89 (m, 4H, H-3′′′), 7.19–7.22 (m, 1H, H-p), 7.24–7.27 (m, 4H, H-2′′′), 7.28–7.31 (m, 2H, H-m), 7.39–7.41 (m, 2H, H-p), 8.33 (s, 1H, H-8′), 8.42 (s, 1H, H-2′), 8.96 (s, 1H, N=CH−NBu₂). ¹³C NMR (150.92 MHz, d6-DMSO): δ 13.77 and 13.95 (2 × CH₃), 19.34 and 19.83 (2 × C-3), 21.37 (C-3′′), 25.45 (C-6′′), 28.88 and 30.69 (2 × C-3), 29.22 (C-7′′), 32.62 (C-2′′), 44.55 and 51.07 (2 × C-1), 47.14 (C-5′′), 48.68 (C-1′′), 55.16 (2 × OCH₃), 57.12 (C-4′′), 66.45 (OCH₂), 74.81 (C-8′′), 84.91 (Ph₃CO−), 113.18 (C-3′′′), 125.64 (C-5′), 126.61 and 127.85 and 127.97 (Ph-o, m, p), 129.96 and 129.98 (C-2′′′), 136.19 and 136.38 (C-1′′′), 140.98 (C-8′), 145.67 (Ph-i), 151.84 Č-2′), 151.88 (C-4′), 158.07 (C-4′′′), 158.13 (N=CH−NBu₂), 159.52 (C-6′). ESI MS, m/z (rel%): 731 (100) [M + H]. HRMS: calcd for [M + H]: 731.42793, found: 731.42774.

(1S,4R,5R,8S)-1-((Bis(4-methoxyphenyl) (phenyl)methoxy)methyl)-4-(6-(((dibutylamino) methylene)amino)-9H-purin-9-yl)bicyclo[3.2.1]octan-8-yl (2-cyanoethyl) diisopropylphosphoramidite (31). Compound 30 (680 mg, 0.93 mmol) and DIPEA (0.71 mL, 4.08 mmol) were dissolved in dry THF (10 mL) and the flask was rinsed several times with argon. Then 2-cyanoethyl N,N-diisopropylchloro-phosphoramidite (0.42 mL, 1.88 mmol) was added dropwise at r.t. for 15 minutes. The reaction mixture was then stirred at r.t. for 3.5 h and then poured to the mixture of a satd solution of sodium bicarbonate with ice (150 mL). The water phase was extracted with ethyl acetate (2 × 250 mL) and the combined organic phases were dried with sodium sulfate and evaporated. The residue was co-evaporated with benzene (2 × 50 mL) and then chromatographed (100 g – deactivated with triethylamine, toluene–ethyl acetate 1 : 9) to afford 693 mg (80%) of the product 31 as a white foam. ³¹P{¹H} NMR (202 MHz, C₆D₆): 147.67, 146.63. ESI MS, m/z (rel%): 931 (100) [M + H]. HRMS: calcd for [M + H]: 931.53578, found: 931.53558; calcd for [M + Na]: 953.51772, found: 953.51730.

Synthesis of oligonucleotides

The oligonucleotides were synthesised from the appropriate monomers on a ∼0.5 μmol scale by a standard trityl-off phosphoramidite method using the LCAA CPG with attached 2′-deoxy-5′-O-dimethoxytritylcytidine-3′-O-hemisuccinate as the first nucleoside. Deprotection and release of oligonucleotides from CPG was achieved with gaseous ammonia (0.7 MPa) at r.t. for 12 h. Oligonucleotides were purified at 55 °C on DNAPac PA100 10 × 250 mm Nucleic Acid Column (Dionex) at a flow rate of 3 mL min⁻¹ using a linear gradient of sodium chloride (20 mM → 500 mM, 60 min) in 50 mM sodium acetate buffer pH 7.0 containing 20% (v) of acetonitrile. Desalting of pure oligonucleotides was performed on 10 μm Luna C18 (2) 10 × 100 mm column (Phenomenex) at a flow rate of 3 mL min⁻¹ using a gradient of acetonitrile (0 → 25%, 30 min) in 0.1 M triethylammonium hydrogencarbonate. Desalted oligonucleotides were freeze-dried and characterized by MALDI TOF (Table 2).

Table 2 Analytical data for oligonucleotides

Oligonucleotide	Calcd mass	Found mass
5′-d(GCA̲^25TA̲^25TCA̲^25C)	2790.82	2790.2
5′-r(GCA̲^25UA̲^25UCA̲^25C)	2858.76	2858.4
5′-d(GCA̲^26TA̲^26TCA̲^26C)	2796.82	2796.2
5′-r(GCA̲^26UA̲^26UCA̲^26C)	2864.76	2864.0

---

Hybridization study

Thermal experiments with oligonucleotide complexes were performed at 260 nm using a CARY 100 Bio UV Spectrophotometer (Varian Inc.) equipped with a Peltier temperature controller and thermal analysis software. The aqueous solutions of modified and natural complementary strands (4 nmol of each) were mixed, freeze-dried and dissolved in 50 mM NaH₂PO₄ – Na₂HPO₄ pH 7.2 with 100 mM NaCl (1 mL) to give a 4 μM duplex solution. A heating–cooling cycle over a range of 15–60 °C with a gradient of 0.5 °C min⁻¹ was applied. The T_m value of each complex was determined from the first derivative plots (dA₂₆₀/dT versus temperature) as the temperature at a local maximum of dA₂₆₀/dT.

Acknowledgements

This study was supported by the Czech Science Foundation (grant no. P207/12/P625) and Gilead Sciences, Inc. (Foster City, CA, USA). Subvention for the development of a research organization (RVO: 61388963) is also acknowledged.

Notes and references

1. (a) C. J. Leumann, Bioorg. Med. Chem., 2002, 10, 841–854; (b) Antisense Drug Technology: Principles, Strategies, and Applications, ed. S. T. Crooke, CRC Press, Boca Raton, 2nd edn, 2007; (c) S. Kauppinen, B. Vester and J. Wengel, Drug Discovery Today Technol., 2005, 2, 287–290.
2. T. Imanishi and S. Obika, Chem. Commun., 2002, 1653–1659.
3. S. Obika, D. Nanbu, Y. Hari, K. Morio, Y. In, T. Ishida and T. Imanishi, Tetrahedron Lett., 1997, 38, 8735–8738.
4. S. K. Singh, P. Nielsen, A. A. Koshkin and J. Wengel, Chem. Commun., 1998, 455–456.
5. (a) R. N. Veedu and J. Wengel, Chem. Biodiversity, 2010, 7, 536–542; (b) T. P. Prakash, Chem. Biodiversity, 2011, 8, 1616–1641.
6. (a) M. A. Campbell, B. Vester and J. Wengel, Nucleic Acid Ther., 2011, 21, A4; (b) K. K. Karlsen and J. Wengel, Nucleic Acid Ther., 2012, 22, 366–370; (c) A. S. Jorgensen, L. H. Hansen, B. Vester and J. Wengel, Bioorg. Med. Chem. Lett., 2014, 24, 2273–2277; (d) M. Hollenstein, Molecules, 2012, 17, 13569–13591.
7. H. Kaur, B. R. Babu and S. Maiti, Chem. Rev., 2007, 107, 4672–4697.
8. J. F. Xu, Y. Liu, C. Dupouy and J. Chattopadhyaya, J. Org. Chem., 2009, 74, 6534–6554.
9. (a) C. Zhou and J. Chattopadhyaya, Chem. Rev., 2012, 112, 3808–3832; (b) P. P. Seth, C. R. Allerson, A. Berdeja, A. Siwkowski, P. S. Pallan, H. Gaus, T. P. Prakash, A. T. Watt, M. Egli and E. E. Swayze, J. Am. Chem. Soc., 2010, 132, 14942–14950.
10. (a) M. Kaura, D. C. Guenther and P. J. Hrdlicka, Org. Lett., 2014, 16, 3311; (b) M. Kaura, P. Kumar and P. J. Hrdlicka, J. Org. Chem., 2014, 79, 6256–6268; (c) P. Kumar, M. E. Østergaard, B. Baral, B. A. Anderson, D. C. Guenther, M. Kaura, D. J. Raible, P. K. Sharma and P. J. Hrdlicka, J. Org. Chem., 2014, 79, 5047–5061.
11. (a) J. Wang, B. Verbeure, I. Luyten, E. Lescrinier, M. Froeyen, C. Hendrix, H. Rosemeyer, F. Seela, A. Van Aerschot and P. Herdewijn, J. Am. Chem. Soc., 2000, 122, 8595–8602; (b) P. Herdewijn and E. De Clercq, Bioorg. Med. Chem. Lett., 2001, 11, 1591–1597; (c) B. Verbeure, E. Lescrinier, J. Wang and P. Herdewijn, Nucleic Acids Res., 2001, 29, 4941–4947; (d) J. Wang, B. Verbeure, I. Luyten, M. Froeyen, C. Hendrix, H. Rosemeyer, F. Seela, A. Van Aerschot and P. Herdewijn, Nucleosides, Nucleotides Nucleic Acids, 2001, 20, 785–788.
12. K. Robeyns, P. Herdewijn and L. Van Meervelt, Artif. DNA: PNA & XNA, 2010, 1, 2–8.
13. M. Ovaere, P. Herdewijn and L. Van Meervelt, Chem. – Eur. J., 2011, 17, 7823–7830.
14. (a) M. Egli, P. S. Pallan, C. R. Allerson, T. P. Prakash, A. Berdeja, J. H. Yu, S. Lee, A. Watt, H. Gaus, B. Bhat, E. E. Swayze and P. P. Seth, J. Am. Chem. Soc., 2011, 133, 16642–16649; (b) P. P. Seth, J. H. Yu, A. Jazayeri, P. S. Pallan, C. R. Allerson, M. E. Østergaard, F. W. Liu, P. Herdewijn, M. Egli and E. E. Swayze, J. Org. Chem., 2012, 77, 5074–5085; (c) M. E. Jung, T. A. Dwight, F. Vigant, M. E. Østergaard, E. E. Swayze and P. P. Seth, Angew. Chem., Int. Ed., 2014, 37, 9893–9897.
15. A. A. Koshkin, J. Fensholdt, H. M. Pfundheller and C. Lomholt, J. Org. Chem., 2001, 66, 8504–8512.
16. E. Abraham, C. W. Bailey, T. D. W. Claridge, S. G. Davies, K. B. Ling, B. Odell, T. L. Rees, P. M. Roberts, A. J. Russell, A. D. Smith, L. J. Smith, H. R. Storr, M. J. Sweet, A. L. Thompson, J. E. Thomson, G. E. Tranter and D. J. Watkin, Tetrahedron: Asymmetry, 2010, 21, 1797–1815.
17. F. H. Wu, R. Hong, J. H. Khan, X. F. Liu and L. Deng, Angew. Chem., Int. Ed., 2006, 45, 4301–4305.
18. M.-H. Filippini, R. Faure and J. Rodriguez, J. Org. Chem., 1995, 60, 6872–6882.
19. K. C. Nicolau, Y.-L. Zhong and P. S. Baran, J. Am. Chem. Soc., 2000, 122, 7596–7597.
20. J. L. Luche, J. Am. Chem. Soc., 1978, 100, 2226–2227.
21. P. S. Jones, P. W. Smith, G. W. Hardy, P. D. Howes, R. J. Upton and R. C. Bethell, Bioorg. Med. Chem. Lett., 1999, 9, 605–610.
22. C. Ding, Y. Zhang, H. Chen, C. Wild, T. Wang, M. A. White, Q. Shen and J. Zhou, Org. Lett., 2013, 15, 3718–3721.
23. M. Dejmek, S. Kovačková, E. Zborníková, H. Hřebabecký, M. Šála, M. Dračínský and R. Nencka, RSC Adv., 2012, 2, 6970–6980.
24. M. Dejmek, M. Šála, P. Plačková, M. Hřebabecký, L. Mascarell Borredà, J. Neyts, M. Dračínský, E. Procházková, P. Jansa, P. Leyssen, H. Mertlíková-Kaiserová and R. Nencka, Arch. Pharm., 2014, 347, 478–485.
25. M. T. Migawa, T. P. Prakash, G. Vasquez, P. P. Seth and E. E. Swayze, Org. Lett., 2013, 15, 4316–4319.
26. M. R. Harnden, P. G. Wyatt, R. B. Boyd and D. Sutton, J. Med. Chem., 1990, 33, 187–196.

---

Footnote

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c4ob02193b

---